Darzalex from J&J, Genmab scores FDA approval in frontline multiple myeloma use as Sanofi rival looms
As Sanofi awaits the FDA review of its multiple myeloma drug — J&J and Genmab’s established rival treatment Darzalex scored US approval for use in treatment …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
